Abstract

PROTOCOL SPECIFIC RESEARCH The Protocol Specific Research program provides data management and other infrastructure support of novel clinical trials designed and implemented by Kimmel Cancer Center members. These trials are innovative, early phase (I or II), and/or pilot studies testing concepts that are likely to lead to expanded, externally funded studies. Since the last grant submission, the investigators at the Kimmel Cancer Center have been committed to the development of investigator-initiated trials. Institutional funds cover experienced support staff for these trials. Funds are being requested to provide financial support for additional clinical research coordinators for the planned investigator initiated trials (IIT). The area of greatest emphasis has been in the development of innovative """"""""first-in-man"""""""" trials of new agents, in conjunction with therapeutic radiation. These trials are conducted with multi-disciplinary leadership including radiation oncologists, medical oncologists, surgical oncologists, and translational scientists. Over the last 6 years, the number of these trials has increased from 3 to 9 active trials. The 9 multi-modality IIT currently open accounted for 60% of the cancer center therapeutic accrual during 2006. As of April, 2007, there are 3 multi-modality IIT trials under active development. The institution will continue to provide funds to support staff for these IIT trials.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-12
Application #
8302957
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-06-01
Project End
2013-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
12
Fiscal Year
2011
Total Cost
$88,118
Indirect Cost

  Institution

Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107

  Publications

Sullivan-Reed, Katherine; Bolton-Gillespie, Elisabeth; Dasgupta, Yashodhara et al. (2018) Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep 23:3127-3136
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Lapadula, Dominic; Farias, Eduardo; Randolph, Clinita E et al. (2018) Effects of Oncogenic G?q and G?11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res :
Vite, Alexia; Zhang, Caimei; Yi, Roslyn et al. (2018) ?-Catenin-dependent cytoskeletal tension controls Yap activity in the heart. Development 145:
McNair, Christopher; Xu, Kexin; Mandigo, Amy C et al. (2018) Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest 128:341-358
Garcia, Samantha A; Lebrun, Aurore; Kean, Rhonda B et al. (2018) Clearance of attenuated rabies virus from brain tissues is required for long-term protection against CNS challenge with a pathogenic variant. J Neurovirol 24:606-615
Vido, Michael J; Le, Kaitlyn; Hartsough, Edward J et al. (2018) BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep 25:1501-1510.e3
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469
Liao, Lili; Liu, Zongzhi Z; Langbein, Lauren et al. (2018) Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. Elife 7:
Heeke, Arielle L; Pishvaian, Michael J; Lynce, Filipa et al. (2018) Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018:

Showing the most recent 10 out of 807 publications